Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II 52-week, randomized, double-blind, placebo-controlled trial of dexpramipexole in patients with severe eosinophilic asthma

Next Previous
Trial Profile

Phase II 52-week, randomized, double-blind, placebo-controlled trial of dexpramipexole in patients with severe eosinophilic asthma

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 09 Dec 2019 New trial record
  • 02 Dec 2019 According to a Knopp Biosciences media release, the company is planning to initiate this study in the first half of 2020.
  • 02 Dec 2019 According to a Knopp Biosciences media release, The clinical program is chiefly funded by the National Institute for Health Research (NIHR) and Medical Research Council (MRC) of the UK, with the drug candidate, matching placebo, and additional support provided by Knopp Biosciences.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top